CPIX - Earnings announcements

$100 million Strategic Transaction Closed Special Shareholder Dividend FundedAdvancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update following the successful closing of its Strategic Transaction with Apotex Health. During the second quarter, Cumberland completed a transaction with Apotex Health, the largest Canadian pharmaceutical company, to integrate their branded business. Under the terms of the agreement, Apotex acquired Cumberland's portfolio of FDA-approved brands and related commer

NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that it will provide a company update with second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026. A conference call will be held on August 4 at 4:30 p.m. Eastern Time to discuss the results and update.Call ParticipationThe link to register is https://register-conf.media-server.com/register/BI2da176d5d0dd4778a44db3d4af6e7b39.Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alt

NASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financial results and provide a company update after the market closes on Tuesday, May 5, 2026. A conference call will be held on May 5 at 4:30 p.m. Eastern Time to discuss the results and update.The link to register is https://register-conf.media-server.com/register/BI31a40566a8cb4846873ec8b25642be3a.Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically c

Cumberland to highlight 2025 financial, international, portfolio and clinical progressNASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $13.7 million during the fourth quarter of 2025, a 31% increase over the prior year period. Net revenues for the full year 2025 were $44.5 million an 18% increase over the prior year period, achieving the company's target of double digit revenue growth. Cumberland en

NASHVILLE, Tenn., Feb. 24, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market closes on Tuesday, March 3, 2026. A conference call will be held on March 3 at 4:30 p.m. Eastern Time to discuss the results and update.The link to register is https://register-conf.media-server.com/register/BI6effc1a9cae9445f9bb0d60817870ffa.Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at

NASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $8.3 million during the third quarter of 2025. Year-to-date revenues for the first nine months of the year totaled $30.8 million, representing an increase of 12% over the first nine months of 2024. Cumberland ended the quarter with approximately $66 million in total assets, $40 million in liabilities and $26 million of shareholders' equity. "We are v

NASHVILLE, Tenn., Oct. 28, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2025 financial results and provide a Company update after the market closes on Tuesday, Nov. 4, 2025. A conference call will be held on Nov. 4 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is: https://register-conf.media-server.com/register/BI93f30c40680943ef8d49bc77222ec17f. Once registered, participants can dial in from their phone using a dial-in and PIN n

NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.8 million during the second quarter of 2025, a 10% increase over the prior year period. Year-to-date revenues for the first six months of the year totaled $22.6 million, representing an increase of 23% over the first half of 2024. Cumberland ended the quarter with approximately $68 million in total assets, $40 million in liabilities and $28 milli

NASHVILLE, Tenn., July 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2025 financial results and provide a Company update after the market closes on Tuesday, August 5, 2025. A conference call will be held on August 5 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is: https://register-conf.media-server.com/register/BI0e0cfee6a381408fa7d3d939d82dfa04. Once registered, participants can dial in from their phone using a dial-in and

NASHVILLE, Tenn., May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period. As a result the Company generated a net profit of $1.3 million for the quarter, adjusted earnings of $2.4 million, and cash flow from operations of $3.9 million. Cumberland ended the quarter with approximately $70 million in total assets, $41.6 million in liabil

NASHVILLE, Tenn., April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 financial results and provide a Company update after the market closes on Tuesday, May 6, 2025. A conference call will be held on May 6 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is: https://register-conf.media-server.com/register/BIea2bc7f82dd24caea135dbe5460d9b6f. Once registered, participants can dial in from their phone using a dial-in and PIN nu

2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval  NASHVILLE, Tenn., March 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.4 million during the fourth quarter of 2024, an 11.6% increase over the prior year period. Net revenues for the full year 2024 were $38 million. Cumberla

NASHVILLE, Tenn., Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial results and provide a company update after the market closes on Tuesday, March 4, 2025. A conference call will be held on March 4 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIafb49dfab9014db59440ff63e1d827b2. Once registered, participants can dial in from their phone using a dial-in and PIN number

–        New Real World Study of 150,000 Patients Favors Caldolor over ketorolac   – –        DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations   – NASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024. The company ended the third quarter of 2024 with $77 million in total assets, $52 million in liabilities and $25 million of shareholders' equity.

NASHVILLE, Tenn., Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes on Thursday, Nov. 7, 2024. A conference call will be held on Nov. 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIdd190691b1df432e9f1f65383f53b384. Once registered, participants can dial in from their phone using a dial-in and PIN

NASHVILLE, Tenn., Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024. Highlights include: $9.9 million in net revenue during the second quarter of 2024, an increase of 16% sequentially from the first quarter of 2024.Adjusted earnings of $0.2 million, which represents a $0.8 million improvement over the prior period in 2024.$78.5 million in assets, $52.5 million in liabilities and $26.3 m

NASHVILLE, Tenn., July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financial results and provide a company update after the market closes on Tuesday, Aug. 6, 2024. A conference call will be held on Aug. 6 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIfa6a94515e5548c28e9d77d03c95a13e. Once registered, participants can dial in from their phone using a dial-in and PIN

NASHVILLE, TENN., May 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders' equity. "It has been a steady start to 2024 – and despite some challenges the biopharmaceutical sector is facing in the financial markets amid stubborn inflation and stalled intere

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024. A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIbb2d35bc9570474dabf8b2e3d2e4ca72. Once registered, participants can dial in from their phone using a dial-in and PIN nu

2023 highlights include expanded FDA approval and new study publications NASHVILLE, Tenn., March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations. Cumberland ended the year with $82 million in total assets – including $18 million in cash, $53 million in liabilities and $30 million of shareholders' equity. "In many ways 2023 was a building year for

NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024. A conference call will be held on March 5 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BI77538b1a0c52414b9e2772846f5498ae.   Once registered, participants can dial in from their phone using a dial-in and PIN num

NASHVILLE, Tenn., Aug. 8, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2023. Highlights include: $10.9 million in revenue during the second quarter, an increase of 6% over the prior year period, and an increase of 18% sequentially from the first quarter of this year.Positive earnings for the second consecutive quarter, with $1.1 million in net income for the first half of the year.Adjusted earn

NASHVILLE, Tenn., Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023. A conference call will be held on Aug. 8 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIeb03c2e461914b7d94f99de2f7535170.    Once registered, participants can dial in from their phone using a dial-in and P

NASHVILLE, Tenn., May 9, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that the Company's product portfolio of FDA-approved brands delivered combined revenues of $9.2 million during the first quarter of 2023. Net income for the period was $0.2 million, or $0.01 a share, resulting in adjusted earnings of $1.7 million, or $0.11 a share. The Company ended the first quarter with $89 million in total assets, $53 million in total liabilities, and $36 million of shareholders' equity. Cumberland will report its

NASHVILLE, Tenn., May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2023 financial results and provide a company update after the market closes on Tuesday, May 9, 2023. A conference call will be held on May 9 at 4:30 p.m. Eastern Time, to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BI723fac45344448bbb1833dbb8fa667f3. Once registered, participants can dial in from their phone using a dial-in and PIN num

2022 highlights include its acquisition of Sancuso® and move to new headquarters NASHVILLE, Tenn., March 7, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company today announced full year 2022 financial results and provided a Company update. Net revenues grew 17% over the prior year to $42 million, resulting in $8 million in cash flow from operations. As of December 31, 2022, the Company's total assets were $93 million, including $20 million in cash. Total liabilities were $57 million and total shareholders' equity was $36 milli

NASHVILLE, Tenn., Feb. 28, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022 financial results and provide a company update after the market closes on Tuesday, March 7, 2023. A conference call will be held March 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIc9d03deed82d47389284c0538fb62962. Once registered, participants can dial in from their phone using a dial-in and PIN number t

Company Also Delivers Growing Cash Flow from Operations NASHVILLE, Tenn., Nov. 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $11.4 million during the third quarter of 2022 - a 41% increase over the prior year period. Cumberland also reported a 19% increase in net revenues for the first nine months of the year compared to the same period in 2021. The Company ended the third quarter with $91 million in total assets, $53 mil

NASHVILLE, Tenn., Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financial results and provide a company update after the market closes on Tuesday, Nov. 8, 2022. A conference call will be held Nov. 8 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BI21ae99e384c446cfb00fbab05f8bf1a3. Once registered, participants can dial in from their phone using a dial-in and PIN numbe

Expanding portfolio of FDA approved brands driving double digit growth NASHVILLE, Tenn., Aug. 9, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $10.3 million during the second quarter of 2022 – a 14% increase over the prior year period. Cumberland also reports a 10% increase in net revenues for the first half of the year compared to the same period in 2021. Year-to-date cash flow from operations were $2.2 million. The Company

NASHVILLE, Tenn., Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug. 9, 2022. A conference call will be held Aug. 9 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIcc5e9791aa7343d9927dca16dc4cf493. Once registered, participants can dial in from their phone using a dial-in and PIN numb

The Nashville-based specialty pharmaceutical company issues first quarter 2022 financial results and a company update NASHVILLE, Tenn., May 10, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company today announced that the Company's product portfolio of FDA-approved brands delivered combined revenues of $11.2 million during the first quarter of 2022, - which is a 6% increase over the prior year period.  Adjusted earnings for the quarter were $0.5 million, or $0.03 a share.  The company ended the first quarter with $96.7 million in total assets, $55.9 million in total liabilities, and $41.0 million of shareholders' equity. Cumberland will repo

NASHVILLE, Tenn., May 3, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2022 financial results and provide a company update after the market closes on Tuesday, May 10, 2022. A conference call and live internet webcast will be held on May 10 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial (877) 303-1298 (for U.S. callers) or (253) 237-1032 (for international callers). A rebroadcast of the teleconference will be available for

NASHVILLE, Tenn., March 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company today announced full year 2021 financial results and provided a company update. Net revenues totaled $36 million, resulting in $6 million in cash flow from operations. As of December 31, 2021, the company's total assets were $84 million, including $27 million in cash. Total liabilities were $42 million, including $15 million on its credit facility and total shareholders' equity was $43 million. "Despite the continued challenges of operating during a

NASHVILLE, Tenn., March 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceuticals company, announced today that it will release annual 2021 financial results and provide a company update after the market closes on Tuesday, March 8, 2022. A conference call and live internet webcast will be held on March 8 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial (877) 303-1298 (for U.S. callers) or (253) 237-1032 (for international callers). A rebroadcast of the teleconference will be available for one wee

NASHVILLE, Tenn., Nov. 2, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release third quarter 2021 financial results and provide a Company update after the market closes on Tuesday, November 9, 2021. A conference call and live internet webcast will be held on November 9 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dial

NASHVILLE, Tenn., Aug. 10, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today is providing a company update and second quarter 2021 financial results. Net revenues from continuing operations during the quarter were $9.1 million and totaled $19.6 million for the first half of 2021. The company also recorded an additional $500,000 in revenue during the second quarter and $1 million year to date, associated with divested product rights for two brands it is no longer distributing. While there was a slight decline in revenu

NASHVILLE, Tenn., Aug. 3, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release second quarter 2021 financial results and provide a Company update after the market closes on Tuesday, August 10, 2021. A conference call and live internet webcast will be held on Tuesday, August 10, 2021, at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be ac